Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer

December 15, 2010 By Bio-Medicine.Org

SAN FRANCISCO and ILLKIRCH, France, Dec. 16, 2010 /PRNewswire/
— Jennerex, Inc., a private clinical-stage biotherapeutics company
focused on the development and commercialization of first-in-class
targeted oncolytic products for cancer, and Transgene (NYSE
Euronext Paris: FR0005175080), a bio-pharmaceutical company
specialized in the development of immunotherapeutic products, today
announced that enrollment and treatment of patients in a Phase 1b
clinical trial has been initiated to evaluate JX-594 in patients
with advanced metastatic, refractory colorectal cancer (CRC).
 The study will be performed in Korea, where Green Cross
Corporation holds market rights for JX-594.

“The initiation of this study marks an important step forward in
the development of JX-594 for a second major oncology indication.
With a significant and growing population of colorectal cancer
patients who have failed existing therapies or for whom existing
therapies are not appropriate, we believe JX-594, with its unique
mechanisms of action and demonstrated tumor response in preclinical
models of CRC, may provide an important new therapeutic modality
for patients around the world suffering from this devastating
cancer,” said David H. Kirn, M.D., president and chief executive
officer of Jennerex.

“The study design for this trial builds on our joint experience
and positive clinical results using JX-594 to treat liver cancer
and represents an important milestone which is our ability to
administer multiple doses intravenously,” added Philippe Archinard,
chairman and chief executive officer of Transgene.

The intravenous, open-label, multi-dose-escalation study is
being conducted at Samsung Cancer Center in Seoul, South Korea. The
study will enroll up to 15 patients with metastatic colorectal
cancer that have failed both oxaliplatin-based and irinotecan-based
chemotherapy regimens, and whose tumors harbor ras mutations and/
or are refractory to Erbitux therapy. Patients en

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech